The infiltration of CAR-T cells to the tumor site is significantly reduced when the chemokine receptor expressed by T cells is not compatible with chemokines secreted by tumor cells, as noted in the case of CXCL-1, CXCL-5, and CXCL-12. This evidence concerns the gene CXCL5 and neoplasm.